Table 1 Strategies combining multi-antigen-targeted CAR-T cells
From: Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
Boolean logic gates | CAR-T cell mode | Target | CAR construction | Indication | Reference |
|---|---|---|---|---|---|
OR | Pooled CAR-T cell | EGFR and CD133 | EGFR-CD137-CD3ζ CD133-CD137-CD3ζ | CAA | Feng et al. 2017 |
Dual CAR-T cell | HER2 and IL-13Rα2 | HER2-CD28-CD3ζ IL13Rα2-CD28-CD3ζ | GBM | Hegde et al. 2013 | |
CD19 and CD123 | CD19-CD137-CD3ζ CD123-CD137-CD3ζ | B-ALL | Ruella et al. 2016 | ||
Tandem CAR-T cell | CD19 and HER2 | CD19-HER2-CD28-CD3ζ | Experimental tumors | Grada et al. 2013 | |
HER2 and IL13Rα2 | HER2-IL13Rα2-CD28-CD3ζ | GBM | Hegde et al. 2016 | ||
CD19 and CD20 | CD19-CD20-CD28- CD137-CD3ζ | B cell malignancies | Zah et al. 2016 | ||
CD20 and HER2 | Nano(CD20-HER2)-CD28-CD3ζ | Experimental tumors | De Munter et al. 2018 | ||
CD22 and CD19 | CD22-CD19-CD137-CD3ζ | R/R B-ALL | Jia et al. 2019 | ||
Trivalent CAR T cell | HER2, IL13Rα2 and EphA2 | HER2-CD28-CD3ζ IL13Rα2-CD28-CD3ζ EphA2-CD28-CD3ζ | GBM | Bielamowicz et al. 2018 | |
AND | Dual CAR-T cell | MSLN and FRa | MSLN-CD3ζ FRa-CD28 | Ovarian cancer | Lanitis et al. 2013 |
CD19 and MSLN GFP and CD19 | α-CD19 SynNotch/α-MSLN-CD137-CD3ζ α-GFP SynNotch/α-CD19-CD137-CD3ζ | Experimental tumors | Roybal et al. 2016 | ||
Trivalent CAR T cell | PSCA, TGFβ and IL4 | PSCA-CD28-CD3ζ TGFβ-CD137 IL4Rα-IL7Rα | Pancreatic cancer | Sukumaran et al. 2018 | |
NOT | Dual CAR-T cell | PSMA and CD19 | PSMA-PD1/CTLA-4 CD19-CD28-CD3ζ | Experimental tumors | Fedorov et al. 2013 |